4.5 Article

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort

Kevin Bigaut et al.

Summary: The TYSTEN observational study evaluated the long-term effects of NTZ treatment in RRMS patients. Results showed a 27.7% cumulative probability of SPMS, with predictive factors including EDSS score increase, new lesions, and relapses, while NEDA-3 was found to be a protective factor.

MULTIPLE SCLEROSIS JOURNAL (2021)

Article Pharmacology & Pharmacy

Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing

Ih Chang et al.

Summary: The study investigated the efficacy of extended-interval dosing of natalizumab in patients switching from every-4-week dosing, finding that every-5-week or every-6-week dosing may maintain efficacy, particularly in patients with body weights <80 kg. However, efficacy of natalizumab decreases as dosing intervals and body weight increase. Model-based simulations were partially validated in independent clinical studies, showing similar outcomes to those predicted by the models.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Article Clinical Neurology

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Marinella Clerico et al.

NEUROTHERAPEUTICS (2020)

Article Clinical Neurology

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

Clara Grazia Chisari et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Article Clinical Neurology

Four cases of natalizumab-related PML: a less severe course in extended interval dosing?

Cristina Scarpazza et al.

NEUROLOGICAL SCIENCES (2019)

Article Clinical Neurology

Efficacy and safety of natalizumab extended interval dosing

Bassem Yamout et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)

Article Pharmacology & Pharmacy

Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis

Kumar Kandadi Muralidharan et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)

Article Clinical Neurology

Extended interval dosing of natalizumab in multiple sclerosis

L. Zhovtis Ryerson et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)

Editorial Material Immunology

NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS PATIENTS: A MULTICENTER EXPERIENCE IN CLINICAL PRACTICE IN ITALY

R. Totaro et al.

INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2014)

Article Clinical Neurology

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Helmut Butzkueven et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)

Article Clinical Neurology

Extended interval dosing of natalizumab: a two-center, 7-year experience

Roberto Bomprezzi et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)

Article Medicine, General & Internal

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Medicine, General & Internal

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

CH Polman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)